Company: JUNS
Filing Date: 2025-11-14
Form Type: 10-Q
Source: 0001493152-25-023603
Chunk: 29

Company: JUPITER NEUROSCIENCES, INC.
Filing Date: 2025-11-14
Form: 10-Q
Item: Item 8
Chunk 29
---
 when needed, we may be required to delay, reduce, or terminate some or all of
our development programs and clinical trials. However, there can also be no assurance that we will be able to raise additional funds
on commercially reasonable terms, if at all.

The
timing, extent, and terms of additional capital the requirements will be on many factors, including:

    ●
    the
    scope, rate of progress and costs of our drug delivery, preclinical development activities, laboratory testing and clinical trials
    for our drug candidate;

    ●
    the
    number and scope of clinical programs we decide to pursue;

    ●
    the
    scope and costs of manufacturing development and commercial manufacturing activities;

    ●
    the
    extent to which we acquire or in-license other drug candidate and technologies;

    ●
    the
    cost, timing and outcome of regulatory review of our drug candidate;

    ●
    the
    cost and timing of establishing sales and marketing capabilities, if our drug candidate receives marketing approval;

    ●
    the
    costs of preparing, filing and prosecuting patent applications, obtaining, maintaining and enforcing our intellectual property rights
    and defending intellectual property-related claims;

    ●
    our
    ability to establish and maintain collaborations on favorable terms, if at all;

    ●
    our
    efforts to enhance operational systems and our ability to attract, hire and retain qualified personnel, including personnel to support
    the development of our drug candidate;

    ●
    The
    amount of profit, if any, generated from the sales of the Nugevia product line;

    ●
    the
    costs associated with being a public company; and

    ●
    the
    cost associated with commercializing our drug candidate, if it receives marketing approval.

See
“Risk Factors” included herein and in our Annual Report on Form 10-K for additional discussion of risks associated
with our capital requirements.

28

Cash
Flows for the Nine months ended September 30, 2025 and 2024

The
following table shows a summary of our cash flows for the nine months ended September 30, 2025 and 2024.

    For
    the Nine months ended 
September 30, 

    2025  
    2024 
  
    Net
    cash flows from operating activities 
    $(3,045,713) 
    $(215,225)
  
    Net
    cash flows from investing